Unlabelled: Organizing pneumonia (OP) is a form of interstitial lung disease that develops in response to acute lung injury. SARS-CoV-2 causes a wide range of lung and extrapulmonary disease, but there are few data suggesting an association between COVID-19 and OP. We describe a patient with COVID-19 pneumonia who developed severe progressive OP with significant morbidity.
Learning Points: COVID-19 pneumonia is one of the secondary causes of organizing pneumonia (OP).Early initiation of steroids in OP is associated with improvement in symptoms and prognosis.A prolonged course of steroids may be needed in COVID-induced OP.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035623 | PMC |
| http://dx.doi.org/10.12890/2023_003787 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Secondary organizing pneumonia after infection.
World J Clin Cases
December 2024
Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand.
This editorial explores the clinical implications of organizing pneumonia (OP) secondary to pulmonary tuberculosis, as presented in a recent case report. OP is a rare condition characterized by inflammation in the alveoli, which spreads to alveolar ducts and terminal bronchioles, usually after lung injuries caused by infections or other factors. OP is classified into cryptogenic (idiopathic) and secondary forms, the latter arising after infections, connective tissue diseases, tumors, or treatments like drugs and radiotherapy.
View Article and Find Full Text PDFTrans-bronchial forceps biopsy for COVID-19 related diffuse parenchymal lung abnormalities.
BMC Pulm Med
December 2024
Medical Department I, Division of Pneumology, University Hospital Carl Gustav Carus, TU Dresden, Fetscherstrasse 74, 01307, Dresden, Germany.
Purpose: The role of lung biopsy for evaluation of persistent chest radiographic abnormalities including secondary organizing pneumonia (OP) in COVID-19 remains uncertain. This study aimed to evaluate the diagnostic value of trans-bronchial forceps biopsy (TBFB) in patients with persistent lung abnormalities on thoracic computed tomography (CT) scan following SARS-CoV-2 infection with particular focus on cases with OP and immunocompromised (IC) patients.
Methods: Descriptive retrospective single center analysis of all TBFB performed for diffuse lung parenchymal changes after COVID-19 03-2020 to 06-2023.
Disease Course, Treatment Response and Relapse in a Group of Patients with a Primary Diagnosis of Cryptogenic Organizing Pneumonia: A Cohort Study.
Tanaffos
January 2024
Department of Pulmonary Medicine, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Background: Cryptogenic organizing pneumonia (COP) is a rare lung condition affecting the bronchioles and alveoli. This study aimed to determine the course of the disease and response to treatment in a group of COP patients.
Materials And Methods: In a cohort study, patients' data including demographic features, chest imaging, spirometry, and blood tests, were recorded.
Multifocal Pulmonary Opacities in an Elderly Smoker.
Cureus
November 2024
Pulmonary and Critical Care Medicine Service, Brooke Army Medical Center, San Antonio, USA.
Organizing pneumonia (OP) directly caused by ongoing cigarette smoking does not appear to have been previously described. Despite OP having pathophysiological features distinct from lung cancer, the two may be confused based on similar clinical, radiological, and histopathological findings. This distinction is further clouded by the dynamic nature of these diseases.
View Article and Find Full Text PDFInvasive mucinous adenocarcinoma harbored exon 14 skipping mutation: case report.
Transl Lung Cancer Res
November 2024
Internal Medicine III, Wakayama Medical University, Wakayama, Japan.
Background: Lung mucinous adenocarcinoma has various genetic alterations, but there are no reported cases with exon 14 skipping mutations. Multiplex genetic testing is commonly assessed in non-small cell lung cancer (NSCLC) and treatment usually comprises molecular targeted drugs. However, the efficacy of molecular targeted drugs in lung mucinous adenocarcinoma is not reported.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!